Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.33 |
| ▸ | CDK2 | P24941 | 6/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.33 |
| ▸ | CDK4 | P11802 | 2/20 | 0.32 |
| ▸ | CCND3 | P30281 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | WDR5 | P61964 | 7/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29559929 | 1.00 | S1PR1 (0.33) | S1PR1CCNA2CDK2CCNA1CDK4 | |
| SCHEMBL29559089 | 0.92 | CCNA2 (0.34) | S1PR1CCNA2CDK2CCNA1CDK4 | |
| SCHEMBL21541763 | 0.92 | CCNA2 (0.34) | S1PR1CCNA2CDK2CCNA1CDK4 | |
| SCHEMBL21541827 | 0.91 | MET (0.36) | S1PR1CCNA2CDK2CCNA1CDK4 | |
| SCHEMBL30359441 | 0.91 | MET (0.36) | S1PR1CCNA2CDK2CCNA1CDK4 | |
| SCHEMBL21541801 | 0.91 | FFAR4 (0.34) | WDR5 | |
| SCHEMBL30359401 | 0.91 | FFAR4 (0.34) | WDR5 | |
| SCHEMBL21541715 | 0.88 | PRKDC (0.37) | WDR5MTOR | |
| SCHEMBL21541779 | 0.88 | CDK4 (0.35) | S1PR1CCNA2CDK2CCNA1CDK4 | |
| SCHEMBL30359425 | 0.88 | PRKDC (0.37) | WDR5MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3567041-A9 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-04-20 | — | — | EP | claimed |
| EP-3567041-A1 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | Impact Therapeutics, Inc (CN) | 2019-11-13 | — | — | EP | claimed |
| EP-3567041-A9 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-04-20 | — | — | EP | disclosed |
| US-10874670-B2 | Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2020-12-29 | — | — | US | disclosed |
| EP-3567041-A1 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | Impact Therapeutics, Inc (CN) | 2019-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874670-B2 | Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof | CHEK1, CHEK2, CDK1 | S1PR1 2498/4885CCNA2 309/4885CDK2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.